Novavax, Inc. (Nasdaq: NVAX) today announced preliminary results from the SHIELD-Utah study (Study of Healthcare Workers and ...

Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, ...

Novavax (NVAX) announced preliminary results from the SHIELD-Utah study that showed Novavax’s COVID-19 Vaccine, Adjuvanted 2024-2025 Formula ...

As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...

Preliminary data showed Novavax's (NVAX) non-mRNA JN.1 COVID-19 vaccine induced lower frequency and severity of short-term side effects and impact on daily life compared with Pfizer-BioNTech mRNA ...

Workers who received Novavax reported 12.5% fewer local reactions than those who received the Pfizer vaccine. Average hours ...

Shares in US biotech Novavax fell more than 20% before the weekend, following remarks from health and human services ...

An advisory panel on vaccines meets, carefully, in the shadow of a health secretary who has often criticized it.

Complex Pandemic Accord negotiations have been under way since 2021, with 13 formal meetings and numerous informal sessions.